Apr. 2 at 1:22 AM
$IFRX Finished my review of the InflaRx patents associated with the INF-scaffold and associated indications. Figured I might as well toss it all into a document, maybe others will find it useful.
Confirmed that INF904 cannot cross the BBB, but the force is strong in that scaffolding…
Some interesting new details in Family 2 of the patents that are public knowledge if you don’t mind sifting through reams of very detailed pages that make up patent filings – Claude to the rescue.
Indications explicitly tagged for patent protection: Ischemic reperfusion renal injury, Obstructive nephropathy, IgA nephropathy, lupus nephritis, ANCA vasculitis, aHUS, FSGS, crescentic glomerulonephritis, CIDP, CIPN, Dermatomyositis, bullous pemphigoid, PASH, PAPASH, CSU, and HS.
“Izicopan’s molecular weight is approximately 629 Da…roughly 40 to 50 percent above the CNS ceiling.”
“Vanqua is an active preclinical competitor in CNS C5aR1. The race is underway.”
https://nobrainerbio.substack.com/p/fp-2-beyond-inf904-what-inflarxs
